Minnesota spin-out Embomedics secures $860k series A for disappearing drug delivery system.

Embomedics, a life sciences spin-out of the University of Minnesota, has raised $860k in a series A round, according to a filing with the SEC.

The round, which was supported by a range of angel investors, will go towards the development of Embomedic’s primary technology. The firm is commercialising medtech developed at Minnesota which acts as a drug delivery system which is then absorbed into the body after release.

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.

Not sure if you have a subscription?